Summary

The Asia Pacific sarcopenia treatment market was valued at US$ 696.85 million in 2022 and is expected to reach US$ 1,164.04 million by 2030; it is estimated to register a CAGR of 6.6% from 2022 to 2030.

Products in Clinical Trial Phases Drive Asia Pacific Sarcopenia Treatment Market

A few major players operating in the sarcopenia treatment market are increasingly focusing on drug development to treat sarcopenia. Novel sarcopenia treatments are currently being developed and tested in clinical trials. A few of these products are mentioned below:

Table 1. Sarcopenia Drug Under Clinical Development

Company Name Interventions Conditions Clinical Trial Stage

Abbott Nutrition Medical Food with AN777

Oral Nutritional Formula Malnutrition

Sarcopenia PHASE3

Nutricia Research Dietary Supplement: Bolus ONS A

Dietary Supplement: Bolus ONS B

Dietary Supplement: Bolus ONS C

Dietary Supplement: Bolus ONS D Sarcopenia PHASE1

Novartis Pharmaceuticals Drug: Bimagrumab Sarcopenia PHASE2

McMaster University Behavioural: Step Reduction Sarcopenia PHASE1

Metabolic Technologies Inc. Dietary Supplement: Placebo

Drug: HMB Plus Vitamin D

Behavioural: Non-Exercise

Behavioural: Exercise Sarcopenia PHASE1

Merck Sharp & Dohme LLC Drug: Comparator MK-077

Drug: Comparator Placebo Sarcopenia PHASE2

Immunotec Inc. Dietary Supplement: Immunocal

Dietary Supplement: Casein Aging and Sarcopenia PHASE2

Lijun Yang Combination Product: 3-Month Intensive Intervention Sarcopenia PHASE4

Regeneron Pharmaceuticals Drug: REGN1033 (SAR391786)

Drug: Placebo Sarcopenia PHASE2

Source: Company Websites and The Insight Partners Analysis

Therefore, the extending pipeline of drugs that are in different stages of clinical development presents significant opportunities for the sarcopenia treatment market growth.

Asia Pacific Sarcopenia Treatment Market Overview

The Asia Pacific sarcopenia treatment market is segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. Asia Pacific is expected to register the fastest CAGR in the global market during the forecast period. Asia is the world's most populated continent with a rapidly aging population, and sarcopenia-related issues are becoming more prevalent in several Asian countries. Asians led extremely different lifestyles and follow different dietary habits than people from the Western world. In Asia, sarcopenia in older individuals is more common in males (prevalence 9.6-22.1%) than females (prevalence 7.7-21.8%). Asian Working Group for Sarcopenia (AWGS) aims to promote sarcopenia research in Asia.

Asia Pacific Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Sarcopenia Treatment Market Segmentation

The Asia Pacific sarcopenia treatment market is categorized into treatment type, distribution channel, and country.

Based on treatment type, the Asia Pacific sarcopenia treatment market is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held the largest Asia Pacific sarcopenia treatment market share in 2022.

In terms of distribution channel, the Asia Pacific sarcopenia treatment market is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held the largest Asia Pacific sarcopenia treatment market share in 2022.

By country, the Asia Pacific sarcopenia treatment market is segmented into China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific sarcopenia treatment market share in 2022.

Abbott Laboratories, Bayer AG, Metagenics LLC, Nestle Health Science SA, Novartis AG, Pfizer Inc, Sanofi SA, Amway Corp, and GSK Plc are some of the leading companies operating in the Asia Pacific sarcopenia treatment market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS

1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Sarcopenia Treatment Market - Key Industry Dynamics
4.1 Asia Pacific Sarcopenia Treatment Market - Key Industry Dynamics
4.2 Market Drivers
4.2.1 Upsurge in Geriatric Population
4.2.2 Rise in Malnutrition and Vitamin Deficiency Among Adults
4.3 Key Market Restraints:
4.3.1 Unavailability of Direct Interventions
4.4 Key Market Opportunities:
4.4.1 Products in Clinical Trial Phases
4.5 Future Trends:
4.5.1 Rising Awareness About Sarcopenia
4.6 Impact of Drivers and Restraints:
5. Sarcopenia Treatment Market - Asia Pacific Market Analysis
5.1 Asia Pacific Sarcopenia Treatment Market Revenue (US$ Million), 2020 - 2030
5.2 Asia Pacific Sarcopenia Treatment Market Forecast and Analysis
6. Asia Pacific Sarcopenia Treatment Market Analysis - By Treatment Type
6.1 Vitamin D and Calcium Supplement
6.1.1 Overview
6.1.2 Vitamin D and Calcium Supplement: Asia Pacific Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
6.2 Protein Supplement
6.2.1 Overview
6.2.2 Protein Supplement : Asia Pacific Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
6.3 Vitamin B12 Supplement
6.3.1 Overview
6.3.2 Vitamin B12 Supplement: Asia Pacific Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
6.4 Others
6.4.1 Overview
6.4.2 Others : Asia Pacific Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
7. Asia Pacific Sarcopenia Treatment Market Analysis - By Distribution Channel
7.1 Pharmacies
7.1.1 Overview
7.1.2 Pharmacies : Asia Pacific Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)
7.2 Retail Channels
7.2.1 Overview
7.2.2 Retail Channels : Asia Pacific Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
7.3 Online Channels
7.3.1 Overview
7.3.2 Online Channels : Asia Pacific Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
7.4 Others
7.4.1 Overview
7.4.2 Others : Asia Pacific Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Sarcopenia Treatment Market - Country Analysis
8.1 Asia Pacific
8.1.1 Asia Pacific Sarcopenia Treatment Market Revenue and Forecast and Analysis - By Country
8.1.1.1 Asia Pacific Sarcopenia Treatment Market Revenue and Forecast and Analysis - By Country
8.1.1.2 China Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
8.1.1.2.1 China Sarcopenia Treatment Market Breakdown by Treatment Type
8.1.1.2.2 China Sarcopenia Treatment Market Breakdown by Distribution Channel
8.1.1.3 India Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
8.1.1.3.1 India Sarcopenia Treatment Market Breakdown by Treatment Type
8.1.1.3.2 India Sarcopenia Treatment Market Breakdown by Distribution Channel
8.1.1.4 Japan Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
8.1.1.4.1 Japan Sarcopenia Treatment Market Breakdown by Treatment Type
8.1.1.4.2 Japan Sarcopenia Treatment Market Breakdown by Distribution Channel
8.1.1.5 South Korea Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
8.1.1.5.1 South Korea Sarcopenia Treatment Market Breakdown by Treatment Type
8.1.1.5.2 South Korea Sarcopenia Treatment Market Breakdown by Distribution Channel
8.1.1.6 Australia Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
8.1.1.6.1 Australia Sarcopenia Treatment Market Breakdown by Treatment Type
8.1.1.6.2 Australia Sarcopenia Treatment Market Breakdown by Distribution Channel
8.1.1.7 Rest of Asia Pacific Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
8.1.1.7.1 Rest of Asia Pacific Sarcopenia Treatment Market Breakdown by Treatment Type
8.1.1.7.2 Rest of Asia Pacific Sarcopenia Treatment Market Breakdown by Distribution Channel
9. Sarcopenia Treatment Market-Industry Landscape
9.1 Overview
9.2 Growth Strategies in the Sarcopenia Treatment Market
9.3 Inorganic Growth Strategies
9.3.1 Overview
9.4 Organic Growth Strategies
9.4.1 Overview
10. Company Profiles
10.1 Abbott Laboratories
10.1.1 Key Facts
10.1.2 Business Description
10.1.3 Products and Services
10.1.4 Financial Overview
10.1.5 SWOT Analysis
10.1.6 Key Developments
10.2 Bayer AG
10.2.1 Key Facts
10.2.2 Business Description
10.2.3 Products and Services
10.2.4 Financial Overview
10.2.5 SWOT Analysis
10.2.6 Key Developments
10.3 Metagenics LLC
10.3.1 Key Facts
10.3.2 Business Description
10.3.3 Products and Services
10.3.4 Financial Overview
10.3.5 SWOT Analysis
10.3.6 Key Developments
10.4 Nestle Health Science SA
10.4.1 Key Facts
10.4.2 Business Description
10.4.3 Products and Services
10.4.4 Financial Overview
10.4.5 SWOT Analysis
10.4.6 Key Developments
10.5 Novartis AG
10.5.1 Key Facts
10.5.2 Business Description
10.5.3 Products and Services
10.5.4 Financial Overview
10.5.5 SWOT Analysis
10.5.6 Key Developments
10.6 Pfizer Inc
10.6.1 Key Facts
10.6.2 Business Description
10.6.3 Products and Services
10.6.4 Financial Overview
10.6.5 SWOT Analysis
10.6.6 Key Developments
10.7 Sanofi SA
10.7.1 Key Facts
10.7.2 Business Description
10.7.3 Products and Services
10.7.4 Financial Overview
10.7.5 SWOT Analysis
10.7.6 Key Developments
10.8 Amway Corp
10.8.1 Key Facts
10.8.2 Business Description
10.8.3 Products and Services
10.8.4 Financial Overview
10.8.5 SWOT Analysis
10.8.6 Key Developments
10.9 GSK Plc
10.9.1 Key Facts
10.9.2 Business Description
10.9.3 Products and Services
10.9.4 Financial Overview
10.9.5 SWOT Analysis
10.9.6 Key Developments
11. Appendix
11.1 About The Insight Partners
11.2 Glossary of Terms